Small transpa­cif­ic team led by Lil­ly, Ever­est vet turns to com­pu­ta­tion­al tools for next wave of pep­tide drug dis­cov­ery

When Ker­ry Blan­chard left Ever­est Med­i­cines in Au­gust 2022 to make room for a CEO with a com­mer­cial back­ground, he didn’t have a full idea of what he was do­ing next. But hav­ing spent the past decade in drug de­vel­op­ment, the sci­en­tist and physi­cian by train­ing knew the di­rec­tion he want­ed to go.

“I’ve been very in­ter­est­ed in mov­ing back in­to dis­cov­ery,” Blan­chard said.

A few months lat­er, he jumped right in with a new start­up, Per­pet­u­al Med­i­cines, that’s fo­cused on ap­ply­ing com­pu­ta­tion­al meth­ods to pep­tide ther­a­pies, which he be­lieves will be the fastest-grow­ing area in phar­ma over the next 20 years. Now, Blan­chard, the co-founder and CEO, is tak­ing the wraps off an $8 mil­lion seed round led by Cheng­wei Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER